FDA whistle-blower Graham blasts new Merck arthritis drug

The arthritis drug that Merck has developed to compete with Celebrex may be as risky for the heart as Vioxx, writes Food and Drug Administration whistle-blower David Graham in an editorial posted online Tuesday by a medical journal.
In considering whether Arcoxia should be approved, “the FDA, academia, and the medical research enterprise are once again faced with the opportunity to forsake common sense by willfully accepting misdirection and disinformation presented in the guise of science,” Graham writes on the Journal of the American Medical Association’s website.

usatoday.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s